loading page

Comparison of immune response against Monkeypox Virus in infected patients and historic or newly vaccinated subjects
  • +8
  • Josè Camilla Sammartino,
  • Irene Cassaniti,
  • Alessandro Ferrari,
  • Antonio Piralla,
  • Bergami Federica,
  • Arena Francesca Adua,
  • Stefania Paolucci,
  • Francesca Rovida,
  • Daniele Lilleri,
  • Elena Percivalle,
  • Fausto Baldanti
Josè Camilla Sammartino
Fondazione IRCCS Policlinico San Matteo Biblioteca
Author Profile
Irene Cassaniti
Fondazione IRCCS Policlinico San Matteo Biblioteca

Corresponding Author:i.cassaniti@smatteo.pv.it

Author Profile
Alessandro Ferrari
Fondazione IRCCS Policlinico San Matteo Biblioteca
Author Profile
Antonio Piralla
Fondazione IRCCS Policlinico San Matteo Biblioteca
Author Profile
Bergami Federica
Fondazione IRCCS Policlinico San Matteo Biblioteca
Author Profile
Arena Francesca Adua
Fondazione IRCCS Policlinico San Matteo Biblioteca
Author Profile
Stefania Paolucci
Fondazione IRCCS Policlinico San Matteo Biblioteca
Author Profile
Francesca Rovida
Fondazione IRCCS Policlinico San Matteo Biblioteca
Author Profile
Daniele Lilleri
Fondazione IRCCS Policlinico San Matteo Biblioteca
Author Profile
Elena Percivalle
Fondazione IRCCS Policlinico San Matteo Biblioteca
Author Profile
Fausto Baldanti
Fondazione IRCCS Policlinico San Matteo Biblioteca
Author Profile

Abstract

Monkeypox virus (MPXV) is a zoonotic disease endemic in the rain forest countries of Central and West Africa. Understanding the immune response in zoonosis is fundamental to prevent and contrast viral spreading. MPXV is a close relative of the Variola (smallpox) virus and vaccination with vaccinia virus give an 85% protection against MPXV. With the emergence of the recent MPXV outbreak, Jynneos vaccine has been proposed to individuals at high-risk of exposure. Comparative data on MPXV immune response in vaccinated or infected subjects is still scarce. Here we described the differences between a group of infected patients in comparison to smallpox or Jynneos vaccinated subjects. The patients’ response is stronger and faster, while the Jynneos vaccinated controls need more time to develop a good immunity. Interestingly, the historic smallpox-vaccinated controls retain a degree of protection, even after years from vaccination, which is most visible in the T-cellular memory that is comparable to the newly vaccinated subjects.
02 Jan 2023Submitted to Journal of Medical Virology
02 Jan 2023Submission Checks Completed
02 Jan 2023Assigned to Editor
02 Jan 2023Review(s) Completed, Editorial Evaluation Pending
03 Jan 2023Reviewer(s) Assigned
24 Jan 2023Editorial Decision: Revise Major
18 Apr 20231st Revision Received
21 Apr 2023Submission Checks Completed
21 Apr 2023Assigned to Editor
21 Apr 2023Review(s) Completed, Editorial Evaluation Pending
21 Apr 2023Reviewer(s) Assigned
25 Apr 2023Editorial Decision: Accept